Liquid biopsies

Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial

Jayaram A, et al. Ann Oncol. 2021


Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer.

Conteduca V, et al. Br J Cancer. 2020


Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis.

Conteduca V, et al. JCO Precision Oncology. 2020


Genome-wide plasma DNA methylation features of metastatic prostate cancer.

Wu A, et al. The Journal of Clinical Investigation. 2020

Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis.

Jayaram A, et al. JCO Precision Oncology. 2019

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.

Conteduca V, et al. European Urology. 2018

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.

Conteduca V, et al. Ann Oncol. 2017

Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.

McDaniel AS, et al. BJU Int. 2017

Plasma AR and abiraterone-resistant prostate cancer.

Romanel A, et al. Sci Transl Med. 2015

Androgen receptor expression in circulating tumour cells from castration resistant prostate cancer patients treated with novel endocrine agents.

Crespo M, et al. Br J Cancer. 2015

Tumor clone dynamics in lethal prostate cancer.

Carreira S, et al. Sci Transl Med. 2014

Clinical trials and international collaborations

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.

Clarke N, et al. Ann. Oncol. 2019

Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate: A Randomized, Open-Label Phase 2 Study.

Attard G, et al. JAMA Oncology. 2019

Sequencing of agents in castration-resistant prostate cancer.

Lorente D, et al. Lancet Oncol. 2015

Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.

Attard G, et al. Clin Cancer Res. 2015

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

Richards J, et al. Cancer Res. 2012


5021 Copy number profiles of primary tumors for risk stratification of advanced prostate cancer: A biomarker study embedded in the multicenter STAMPEDE trial.

Grist E, et al. ASCO 2021

Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.

Gilson C, et al. JCO Precision Oncology. 2020

P - 182 Tumour Infiltrating Lymphocytes assessment in the STAMPEDE cohort: association of brisk inflammation with high grade histology.

Mendes L, et al. EACR-AACR-ASPIC Tum Microenvironment 2020

153 Multiregion expression profiling of prostate cancer from men randomized in the STAMPEDE trial: Stage I results of a multistage biomarker analysis.

Grist E, et al. GU ASCO 2020

39 Copy number profiling of STAMPEDE trial patients to improve targeting of existing therapies for advanced hormone-sensitive prostate cancer.

Grist E, et al. EACR Cancer Genomics Conference 2019

88 Whole genome expression analysis of diagnostic patient samples enrolled in the STAMPEDE clinical trial in advanced prostate cancer.

Parry M, et al. EACR Cancer Genomics Conference 2019

29P - Implementing molecular characterisation of prostate cancer tissue from patients recruited to the multi-centre STAMPEDE trial: The STRATOSPHERE consortium

Grist E, et al. MAP. 2018


Editorials and Reviews

Plasma DNA Analysis in Prostate Cancer: Opportunities for Improving Clinical Management.

Wu A, Attard G. Clin Chem 2019.

Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test.

Jayaram A, Wetterskog D, Attard G, Cancer Discov. 2018.

Selected publications